Clinical Trial Update: Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of Remibrutinib after switching from Ocrelizumab in people with Relapsing multiple sclerosis; currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)
• Remibrutinib (remibrutinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: RECRUITING